Overview

• The device uses a biochip to detect active EGFRs in extracellular vesicles from blood samples.
• Tests can be completed in less than 60 minutes with high sensitivity and selectivity.
• Each biochip costs under $2, making the test affordable and accessible.
• The technology can potentially be adapted for other diseases such as pancreatic cancer and cardiovascular disorders.
• Early detection through this method could improve survival rates for glioblastoma patients.